Clinical evaluation of ID NOW influenza A & B 2, a rapid influenza virus detection kit using isothermal nucleic acid amplification technology - A comparison with currently available tests. Issue 2 (February 2020)

• Record Type: Journal Article
• Authors: Mitamura, Keiko; Shimizu, Hideaki; Yamazaki, Masahiko; Ichikawa, Masataka; Abe, Takashi; Yasumi, Yuki; Ichikawa, Yoko; Shibata, Toru; Yoshihara, Masaaki; Shiozaki, Ken; Baba, Shinji; Kudo, Yoshihiro; Tokushima, Masahiko; Konomi, Yasushi; Kawakami, Chiharu
• Is Part Of: Journal of infection and chemotherapy. Volume 26:Issue 2(2020:Feb.)
• Page Start: 216
• Page End: 221
• Publication Date: 2020-02
• Subjects: Influenza -- ID NOW influenza A & B 2 -- Isothermal nucleic acid amplification -- Point-of-care testing -- Rapid antigen detection test; Chemotherapy -- Periodicals; Infection -- Periodicals; Communicable diseases -- Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1016/j.jiac.2019.08.015
• Languages: English
• ISSNs: 1341-321X

Abstract

Abstract: In this study, we evaluated the performance of ID NOW Influenza A & B 2 (ID NOW 2), a rapid molecular point-of-care test for influenza within 13 min, in comparison with currently available tests. A total of 254 nasopharyngeal swabs (NPS) and 271 nasopharyngeal aspirates (NPA) collected from 373 children and 152 adults with influenza-like illness were tested using ID NOW 2, viral culture, rapid antigen detection test, and loop-mediated isothermal amplification test to evaluate the sensitivity and specificity compared with real-time reverse transcription polymerase chain reaction as the reference method. The sensitivities of ID NOW 2 for influenza A were 95.9% and 95.7% in NPS and NPA, respectively, and for influenza B were 100% and 98.7% in NPS and NPA, respectively. The specificity was 100% for both influenza A and influenza B in NPS and NPA. Sensitivity of each test method reflected the difference of analytical sensitivity among the tests, and ID NOW 2 was not affected by time after illness onset and patient age. In conclusion, ID NOW 2 demonstrated a high sensitivity and specificity that is useful for diagnosis of influenza in the clinical setting and infection control.